CSPC Pharmaceutical Gets China Nod for Clinical Trial of Tumor Drug

MT Newswires06:29 ET

CSPC PHARMA (01093.HK): SYH2059 tablets have received approval for clinical trials.

Gelonghui, January 7丨CSPC PHARMA (01093.HK) announced that its developed SYH2059 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. This product was developed by the group's innovative small molecule drug design platform and is a completely new high-activity and highly selective phosphodiesterase 4B (PDE4B) inhibitor with complete自主知识产权. PDE4B inhibitors exert anti-inflammatory and anti-fibrotic effects by regulating the release of inflammatory indicators and inhibiting the proliferation and differentiation of fibroblasts. The approved clinical indication for this trial is interstitial.

Gelonghui Finance04:29 ET

Express News | CSPC Pharmaceutical - Approval Granted by National Medical Products Administration

Reuters04:28 ET

Express News | CSPC Pharmaceutical - Syh2059 Tablets Obtains Clinical Trial Approval

Reuters04:28 ET

CSPC PHARMA (01093.HK) spent 29.3965 million Hong Kong dollars to repurchase 6.55 million shares on January 7.

Gelonghui January 7th丨CSPC PHARMA (01093.HK) announced that on January 7, 2025, it spent 29.3965 million Hong Kong dollars to repurchase 6.55 million shares, with a repurchase price of 4.46-4.53 Hong Kong dollars per share.

Gelonghui Finance04:22 ET

Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.

Track the entire lifecycle of the main sector.

cls.cn20:20 ET